EGFR and head and neck squamous cell carcinoma: Measurement of COX-2 and fibronectin levels in HNSCC may provide clinically useful prognostic biomarkers in HNSCC metastasis and combinatorial inhibition of both COX-2 and fibronectin might provide a novel therapeutic approach for EGFR-overexpressing HNSCC.